Skip to main content

JHOP - March 2021 Vol 11 Special Feature

HOPA Abstracts
HOPA Abstracts
HOPA Abstracts, Gynecologic Cancers, Screening
Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair-Deficient or -Proficient Endometrial Cancer: Results from the GARNET Study
Abstract #CT11
Read More
HOPA Abstracts, Chemotherapy, COVID-19
Operation Angel on the Line: Oncology Pharmacist and Pharmacy Students Piloting a New Oral Chemotherapy Telehealth Clinic During the COVID-19 Pandemic
Abstract #PM07
Read More
HOPA Abstracts
Integration of a Clinical Pharmacist in a Phase 1 Clinical Trial Program
Abstract #PM06
Read More
HOPA Abstracts, Chemotherapy
Feasibility and Perceived Benefit of an Oral Chemotherapy Pharmacy Monitoring Program to Assess Symptom Burden and Medication Adherence in Patients with Cancer
Abstract #PM05
Read More
HOPA Abstracts, Infusion Issues
The Incidence of Coring Between the Traditional Syringe and Needle Compounding Technique and Closed-System Transfer Devices
Abstract #PM04
Read More
HOPA Abstracts, Chemotherapy
Safety of Switching e-Prescribing Platform Body Surface Area Calculation from DuBois & DuBois to Mosteller on Active Chemotherapy Doses
Abstract #PM03
Read More
HOPA Abstracts, Adverse Events
Impact of Drug Repository Program in a Rural Oncology Clinic
Abstract #PM02
Read More
HOPA Abstracts, Adverse Events, Chemotherapy
Evaluation of Treatment Abandonment and Delay with Anticancer Agents at an Outpatient Community Hospital Cancer Center Oral Chemotherapy Clinic: A Retrospective Cohort Analysis
Abstract #PM01
Read More
HOPA Abstracts, Adverse Events
Evaluation of the Relationship between Hypoalbuminemia and Oral Anticancer Drug-Related Adverse Events in Adults with Solid Tumor Malignancies
Abstract #CT14
Read More
HOPA Abstracts, Multiple Myeloma, Vaccinations
Worldwide Influenza and Pneumococcal Vaccination Rates in Patients with Multiple Myeloma, and the Impact of Vaccination on Infection, Hospitalization, and Death
Abstract #CT13
Read More
HOPA Abstracts, Leukemia, Thromboembolism
The Incidence of Arterial and Venous Thromboembolism in Patients with Chronic Myeloid Leukemia or Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Who Are Treated with Ponatinib
Abstract #CT12
Read More
HOPA Abstracts
Welcome to the First Annual Issue of HOPA Abstracts, 2021
Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Read More
HOPA Abstracts, Leukemia, Lymphoma
Results from informCLL, a Prospective Observational Registry: Prognostic Biomarker Testing, Treatment Patterns, and Dosing in 1461 Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Abstract #CT10
Read More
HOPA Abstracts, Myelofibrosis
Real-World Dosing Patterns of Ruxolitinib Among Patients with Myelofibrosis: A US Community Oncology Practice
Abstract #CT09
Read More
HOPA Abstracts, Multiple Myeloma
In-Class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Updated Real-World Results from the Community-Based US MM-6 Study
Abstract #CT08
Read More
HOPA Abstracts, Adverse Events, Leukemia
Incidence of Adverse Effects in Patients with Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia in Lymphoid Blast Crisis Receiving Ponatinib with or without Concomitant Azole Antifungals
Abstract #CT07
Read More
HOPA Abstracts, Colorectal Cancer
Encorafenib plus Cetuximab, with or without Binimetinib, for BRAF V600E–Positive Metastatic Colorectal Cancer: Relationship Between Carcinoembryonic Antigen and Clinical Outcomes from BEACON CRC
Abstract #CT06
Read More
HOPA Abstracts, Cost of Care
Cost of Cancer Management by Stage of Diagnosis Among Medicare Beneficiaries
Abstract #CT05
Read More
HOPA Abstracts, Multiple Myeloma
Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-Label, Multicenter, Phase 1b PAVO Study
Abstract #CT04
Read More
HOPA Abstracts, Targeted Therapies, Screening
Correlation of BRAF Mutation Status in Circulating Tumor DNA with Tumor Biopsy and Clinical Outcomes in the COLUMBUS Study
Abstract #CT03
Read More
HOPA Abstracts, Multiple Myeloma
Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Patients with Multiple Myeloma Receiving Lenalidomide, Bortezomib, and Dexamethasone
Abstract #CT02
Read More